HD Labs Retatrutide 10 Vial

HD Labs Retatrutide 10mg: SA Buyer’s Guide 2026

HD Labs Retatrutide 10mg is an unregistered research peptide sold in South Africa as a lyophilised vial. It’s a lower-cost, lower-volume option compared to the 32mg format — useful for buyers running shorter protocols or testing tolerance before committing to a larger vial. SAHPRA has not evaluated it for safety or efficacy, and Eli Lilly’s retatrutide remained in phase 3 development through 2024–2025 with regulatory submissions anticipated from 2026 onward.

Key Takeaways

• The 10mg vial covers about 5 weeks at 2mg/week; the larger 32mg vial drops cost-per-dose considerably once you reach 4mg/week maintenance.
• Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) that produced roughly 23–24% mean weight loss in a phase 2 trial, ahead of tirzepatide and semaglutide in early cross-trial data.
• Reconstitution takes a few minutes; slow titration (2mg → 4mg → 6mg over 12 weeks) is the primary lever for managing nausea and GI side effects.
• SAHPRA has not registered retatrutide; it is sold as research material only. Section 21 named-patient access via a licensed prescriber is the legal alternative.
• Expect GI side effects (nausea, constipation, fatigue) in the first 1–2 weeks after each dose increase; these typically resolve within 7–14 days.

What Is HD Labs Retatrutide? (2026 Overview)

HD Labs Retatrutide is a research-grade lyophilised peptide replicating Eli Lilly’s investigational compound LY3437943, a triple agonist that binds the GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor is what separates it mechanistically from semaglutide and tirzepatide: the glucagon pathway is associated with increased hepatic glucose output and resting energy expenditure in ways the other two are not. Early trial data show steeper percentage weight loss than either predecessor, though across separate trials rather than head-to-head.

HD Labs is a research-peptide brand stocked by South African resellers including Beskinny, where the 10mg vial sits alongside the 32mg vial and the HD Retatrutide 32 pre-filled pen format. The molecule has an elimination half-life of approximately 6 days, supporting once-weekly subcutaneous dosing in the published trial protocols.

Retatrutide vs other GLP-1 class peptides

Peptide	Receptor targets	Dosing frequency	Phase 2/3 weight loss
Semaglutide	GLP-1 only	Weekly	~15% (STEP 1, 2021)
Tirzepatide	GIP + GLP-1	Weekly	~20–22.5% at 72 weeks
Retatrutide	GIP + GLP-1 + glucagon	Weekly	~23–24% at 48 weeks (phase 2)

Retatrutide activates three metabolic receptors in one molecule, which is the mechanistic basis for its higher reported weight-loss percentages in phase 2 data. The glucagon component drives hepatic glucose suppression and increases resting energy expenditure — two pathways absent in dual or single agonists.

Clinical evidence is still maturing. Phase 3 readouts are expected from 2026 onward, and consumer drug portals continue to list retatrutide as investigational. South African regulatory status diverges sharply from any US milestone. SAHPRA has not registered retatrutide, so HD Labs vials sold locally remain unregistered research material regardless of what happens on the FDA timeline.

10mg vs 32mg: Which Format Is Right for You?

The 10mg vial suits first-time retatrutide users starting at 2mg/week or anyone wanting a low-commitment trial. The 32mg vial wins on cost-per-dose for users already titrated to 4–6mg/week. Both contain the same lyophilised tri-agonist peptide. The difference is total milligrams per vial, reconstitution volume, and what that does to your rand-per-dose calculation.

Side-by-side format comparison

Spec	HD Labs Retatrutide 10mg	HD Labs Retatrutide 32mg
Total peptide	10 mg lyophilised	32 mg lyophilised
Best-fit user	Beginners, titration phase, trialists	Experienced users at 4–6 mg/week, maintenance
BAC water (typical research range)	2 mL → 5 mg/mL, or 4 mL → 2.5 mg/mL	4–8 mL depending on target concentration
Doses at 2 mg/week	5	16
Doses at 4 mg/week	2.5	8
Doses at 6 mg/week	~1.6	~5.3
ZAR price (2026)	R1,400 (Beskinny.store)	R2,049 (other local resellers)
Cost per 2 mg dose	R280	~R128
Cost per 4 mg dose	R560	~R256
Cost per 6 mg dose	n/a (under-filled)	~R386
Reconstitution events per 32 mg supply	3+ vials	1 vial
Storage post-reconstitution	About 4 weeks refrigerated at 2–8°C	About 4 weeks refrigerated at 2–8°C

When the 10mg vial is the smarter buy

Pick the HD Labs Retatrutide 10mg if you’re starting the standard titration ladder at 2mg/week for the first month. One vial covers a full 5-week induction at R280 per dose. If you decide retatrutide isn’t tolerable, you’ve risked R1,400 instead of R2,049. That lower financial exposure is the main reason first-time users choose the 10mg format — if side effects force a stop, you haven’t paid for eight weeks of peptide you’ll never use.

The 10mg format also works if you split doses across two vials to manage expiry risk on a single reconstituted batch. Each vial can be opened and stored separately.

When the 32mg vial pays off

The HD Labs Retatrutide 32mg vial drops cost-per-dose to roughly R128 at 2mg and R256 at 4mg — a large saving versus buying three 10mg vials to cover the same eight weeks. You reconstitute once rather than three times, which reduces sterility breach points and saves on bacteriostatic water.

The trade-off is shelf life. An 8-week supply at 4mg/week sits inside the typical post-reconstitution window only if you dose on schedule. Users who’d rather skip reconstitution entirely should compare the HD Retatrutide 32 Pre-filled Pen, covered in the format FAQ below.

Prices verified 2026; check live listings before ordering.

How to Reconstitute the HD Labs Self-Mix Vial

Reconstitute the HD Labs Retatrutide 10mg vial by injecting 1mL of bacteriostatic water down the inside wall, swirling gently until clear, then refrigerating at 2–8°C. That yields a 10mg/mL solution, so a 2mg dose draws to 0.2mL (20 units on a U100 insulin syringe). These are general research-peptide handling guidelines. Confirm with a licensed healthcare professional before any self-administration.

Supplies needed before opening the vial

• 1 vial HD Labs Retatrutide (10mg or 32mg)
• Bacteriostatic water (typically a 10mL multi-dose vial of 0.9% benzyl alcohol BAC water)
• 1mL U100 insulin syringes (29–31 gauge)
• A 3mL syringe with an 18–21G drawing needle for the BAC water transfer
• Alcohol swabs and a clean, dry surface

Step-by-step reconstitution

1. Wipe both rubber stoppers (BAC water and peptide vial) with separate alcohol swabs and let them air dry.
2. Draw your BAC water volume. Use 1mL for the 10mg vial (10mg/mL) or 2mL for the 32mg vial (16mg/mL). A 2mL draw on a 10mg vial gives 5mg/mL, which is easier to measure at sub-2mg starter doses.
3. Inject the BAC water slowly down the side wall of the peptide vial. Don’t squirt it directly onto the lyophilised powder and don’t shake.
4. Swirl gently for 10–20 seconds until the powder dissolves into a clear solution. Cloudiness or visible particulate means discard the vial.
5. Label the vial with reconstitution date and concentration.
6. Refrigerate at 2–8°C between doses. General handling practice puts the usable window at roughly 28 days post-reconstitution; confirm against your supplier’s batch documentation.

Draw volumes by dose (U100 insulin syringe)

Dose	10mg vial + 1mL BAC (10mg/mL)	10mg vial + 2mL BAC (5mg/mL)	32mg vial + 2mL BAC (16mg/mL)
2mg	0.20mL (20 units)	0.40mL (40 units)	0.125mL (~12–13 units)
4mg	0.40mL (40 units)	0.80mL (80 units)	0.25mL (25 units)
6mg	0.60mL (60 units)	n/a (exceeds syringe)	0.375mL (~37–38 units)

Before injecting, let the drawn syringe sit for 60–90 seconds to reach room temperature. Swab the abdomen, thigh, or upper arm, and rotate sites weekly to reduce lipohypertrophy risk. Buyers who want to skip mixing entirely should compare the HD Retatrutide 32 Pre-filled Pen against the HD Labs Retatrutide 32mg vial on cost-per-dose before ordering.

Dosage Protocol: Starting, Titrating, and Maintaining

Start at 2mg subcutaneous once weekly, hold for 3–4 weeks, then increase by 2mg increments only if gastrointestinal side effects have settled. Retatrutide’s half-life of roughly 6 days is why once-weekly dosing produces stable plasma levels.

Slow titration is the single biggest lever you have for keeping nausea, reflux, and constipation manageable. Each dose step gives your GI tract time to adapt before the next increase.

The 10mg vial covers the entire conservative starting phase. At 2mg/week, one vial gives you five weeks of injections with a small residual, taking you cleanly through the introductory window before any decision to step up. Buyers who plan to titrate past 6mg/week long-term will burn through 10mg vials quickly and should price-compare against the HD Labs Retatrutide 32mg vial on cost-per-mg.

Week-by-week titration reference

A common cautious schedule for research-peptide users, applying the four-week stepwise principle used in the trial protocols:

Week	Weekly dose	Cumulative mg used	Vial coverage
1–4	2mg	8mg	10mg vial (1 vial)
5–8	4mg	16mg	10mg + 32mg, or 2× 10mg
9–12	6mg (if tolerated)	24mg	32mg vial
13–16	8mg (maintenance, if needed)	32mg	32mg vial

The 2023 phase 2 trial reported mean weight loss of about 23–24% at 48 weeks on 8–12mg weekly, so the 4–8mg maintenance band sits below maximal trial dosing but reflects what most users tolerate without significant GI disruption. Published phase 3 protocols may use different titration intervals and ceilings. Verify against primary trial data before extending beyond 8mg/week.

This is not medical advice. Retatrutide has not been evaluated or registered by SAHPRA, and any dose decision should be confirmed with a licensed prescriber familiar with your medical history.

Side Effects and What to Expect During Titration

Expect GI side effects during the first 1–2 weeks of each dose increase: nausea, reduced appetite, constipation or loose stools, mild fatigue, and occasional dizziness. These are consistent with the GLP-1/GIP/glucagon tri-agonist class and typically ease as your body adapts before the next titration step.

Nausea comes from delayed gastric emptying, a known effect of GLP-1 receptor activation that usually resolves within 7–14 days as the stomach adjusts.

The side-effect profile reported in the phase 2 trial mirrors what tirzepatide and semaglutide users describe, with intensity loosely tied to how aggressively you escalate. Slow titration (the 2mg → 4mg → 6mg schedule outlined earlier) is the single biggest predictor of tolerability.

Common vs serious side effects

Category	Symptoms	Typical timing	Action
Common GI	Nausea, vomiting, constipation, diarrhoea	First 3–10 days after each dose step	Smaller meals, hydration, avoid fried/high-fat food
Common systemic	Fatigue, mild dizziness, injection-site redness	First week of escalation	Inject at night; reassess if persistent past 2 weeks
Rare/serious	Severe abdominal pain radiating to back (possible pancreatitis), persistent vomiting, jaundice, allergic reaction (rash, swelling, breathing difficulty)	Any time	Stop dosing immediately and seek medical care

Retatrutide has no approved label of its own, so class-based cautions from the approved GLP-1/GIP incretins apply by extension. In particular, class prescribing information contraindicates use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 (Multiple Endocrine Neoplasia type 2); a history of pancreatitis or gallbladder disease is a further reason not to self-prescribe. Anyone in these groups should not use retatrutide without specialist input.

Practical mitigation

Injecting on a Friday or Saturday night lets you sleep through the worst of the nausea window. Keep meals under ~500 kcal and low-fat for the first 48 hours after each shot. Electrolytes help with the dizziness some users report at 6mg+, particularly in SA’s summer months when dehydration compounds the effect.

If you’re escalating past 4mg and finding side effects unmanageable, holding at the current dose for an extra 2–4 weeks before stepping up is more useful than splitting doses. Buyers who plan to stabilise at 4–6mg long-term will get better cost-per-dose economics from the HD Labs Retatrutide 32mg vial or the HD Retatrutide 32 Pre-filled Pen than from repeat 10mg purchases.

Quantitative real-world incidence rates outside the trial cohort are not yet published in peer-reviewed form as of 2026. Vendor product copy is not a substitute for clinical data, and any persistent or severe symptom warrants stopping the peptide and consulting a licensed prescriber.

SAHPRA Regulatory Context: Buying Peptides in South Africa

Retatrutide does not hold SAHPRA registration as an approved medicine for human use in South Africa as of 2026. SAHPRA is the statutory body governing medicines, medical devices, and related health products under the Medicines and Related Substances Act. Because retatrutide is not on the SAHPRA medicines register, it cannot be lawfully dispensed by a licensed SA pharmacy as a scheduled prescription medicine. Any local sale is framed as a research peptide rather than a finished therapeutic product.

What “research peptide” means for the buyer

You are buying a substance labelled for laboratory use, not a SAHPRA-evaluated medicine with assessed safety, efficacy, or manufacturing oversight. Retatrutide is still an investigational compound in ongoing clinical trials rather than an approved product, and any regulatory documentation issued in other jurisdictions confers no South African marketing authorisation.

Buyers concerned about legal standing should know that purchasing unregistered peptides online sits in a grey zone. SAHPRA enforcement focuses on dispensing by pharmacies rather than individual possession, but the regulatory risk remains real.

Section 21 and the legal alternative

SAHPRA’s Section 21 pathway allows a registered SA prescriber to apply for named-patient access to an unregistered medicine on a case-by-case basis. That route is distinct from purchasing grey-market vials online. It involves a doctor, a documented clinical rationale, and SAHPRA review. If you want a legally clean path to retatrutide in SA, Section 21 via a licensed practitioner is the formal channel.

Compliance disclaimer

Disclaimer: HD Labs Retatrutide (including the 10mg vial, the 32mg vial, and the HD Retatrutide 32 Pre-filled Pen) is sold as a research peptide. It is not SAHPRA-registered, not evaluated for safety or efficacy in humans by SAHPRA, and not a substitute for medical care. Consult a licensed South African healthcare professional before any use. ASA/ARB advertising rules prohibit therapeutic claims on unregistered products.

Retatrutide vs Tirzepatide vs Semaglutide: How They Compare

Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), tirzepatide is a dual agonist (GIP + GLP-1), and semaglutide targets GLP-1 alone. The glucagon receptor adds hepatic glucose suppression and increased energy expenditure, which is why retatrutide shows higher weight loss in early trials despite shorter follow-up periods.

Peptide	Mechanism	Phase 2/3 weight loss	Dosing	SA availability
Semaglutide	GLP-1 mono-agonist	~15% at 68 weeks (STEP 1, 2021)	Weekly	Registered (Ozempic/Wegovy); research-grade peptides also sold
Tirzepatide	GIP + GLP-1 dual	~20–22.5% at 72 weeks (SURMOUNT-1, 2022)	Weekly	Mounjaro registered; HD Labs research vials/pens sold locally
Retatrutide	GIP + GLP-1 + glucagon triple	~23–24% at 48 weeks on 8–12 mg (phase 2, 2023)	Weekly	Not SAHPRA-registered; sold as research peptide only

No head-to-head trial between retatrutide and tirzepatide has been published as of 2026. The percentages above come from separate trials with different durations and populations. Full phase 3 retatrutide weight-loss data was not yet published in peer-reviewed form at the time of writing. The shorter phase 2 window (48 weeks vs 72 weeks for tirzepatide) makes direct comparison awkward, because weight loss typically continues to accrue over longer periods.

The practical read: retatrutide currently shows the largest reductions in early data but carries the thinnest long-term safety record and zero SA regulatory footprint. Buyers who have plateaued on semaglutide or tirzepatide are the typical reason people move up the ladder. If you’re still deciding between formats inside the HD Labs range, the HD Labs Retatrutide 32mg vial and the HD Retatrutide 32 Pre-filled Pen are worth comparing on cost-per-mg before committing to the 10mg vial.

Where to Buy HD Labs Retatrutide in South Africa

Beskinny.store is currently among the more transparent South African stockists of HD Labs Retatrutide, listing the 10mg vial at R1,400 with live stock counts shown on the product page. The 32mg vial sits at around R2,049 from competing local resellers in 2026, which works out cheaper per milligram if your weekly dose is already titrated past 4mg. Prices move with import duties, expiry windows, and exchange rates, so verify on the live product page before ordering.

What a legitimate SA peptide supplier looks like

Four things separate a credible local stockist from a drop-shipper:

• Pricing in ZAR, not USD conversions — no hidden FX surprises at checkout.
• Clear product labelling showing lot, mg per vial, and lyophilised format.
• Live stock counts rather than indefinite “available on backorder” listings.
• Responsive support that answers reconstitution and shipping questions in writing.

Compare the two HD Labs formats directly before committing: the HD Labs Retatrutide 32mg vial suits buyers already at maintenance doses, while the HD Retatrutide 32 Pre-filled Pen removes the reconstitution step entirely for users who would rather not mix BAC water themselves.

Frequently Asked Questions

The five questions below cover what SA buyers ask most often after reading the 10mg vs 32mg comparison. Pricing reflects 2026 figures from Beskinny.store; confirm live before ordering.

Question	Short Answer
Doses per 10mg vial?	5 weekly doses at 2mg; 2–3 at 4mg
Prescription needed?	Not SAHPRA-registered; sold as research peptide
Vial vs pen?	Vial needs BAC water mixing; pen is ready-to-inject
Storage after mixing?	2–8°C, use within about 28 days
Useful after semaglutide plateau?	Possibly, due to glucagon receptor activity

How many doses are in the HD Labs Retatrutide 10mg vial?

At a 2mg weekly starting dose, the 10mg vial yields 5 weekly doses. Once titrated to 4mg/week, the same vial covers 2–3 weeks — the point where the HD Labs Retatrutide 32mg vial becomes the cheaper per-milligram option. The math shifts because you’re using more total milligrams per week, so the fixed cost of the larger vial spreads across more doses.

Do I need a prescription to buy retatrutide in South Africa?

Retatrutide is not a SAHPRA-registered medicine for human use in South Africa as of 2026 and is sold locally as a research peptide. Anyone considering use should consult a licensed healthcare professional, since Section 21 named-patient access is the only legal route to a regulated supply.

What is the difference between the vial and the pre-filled pen format?

The self-mix vial requires reconstitution with bacteriostatic water. The HD Retatrutide 32 Pre-filled Pen ships ready to inject at roughly R2,699 in 2026. The pen costs more per milligram but removes mixing, syringe-drawing, and sterility risk from the workflow. For users uncomfortable with needle handling or reconstitution, the pen removes those friction points.

How should I store the reconstituted vial?

Refrigerate the reconstituted solution at 2–8°C and use it within about 28 days, consistent with general lyophilised-peptide handling guidance. Keep the vial upright, away from light, and discard if the solution turns cloudy or develops particulates. This window reflects common handling practice rather than a SAHPRA-approved shelf life or a retatrutide-specific stability study; confirm storage against your supplier’s batch documentation.

Can I use retatrutide if I have plateaued on semaglutide?

Retatrutide’s added glucagon receptor activity is what differentiates it from single GLP-1 agonists like semaglutide. The phase 2 trial showed mean weight loss of around 23–24% at 48 weeks on 8–12mg weekly. A licensed prescriber should make the switch call based on your full clinical picture, because the glucagon pathway may offer additional metabolic benefit in users who have adapted to GLP-1 alone.

Next Steps

If you’re a first-time retatrutide user, start with the HD Labs Retatrutide 10mg vial and follow the 2mg/week titration schedule outlined above. Confirm reconstitution and dosing with a licensed healthcare professional before your first injection. Once you’ve completed 4–6 weeks at 2mg and confirmed tolerability, reassess whether to step up to 4mg or switch to the 32mg vial for cost savings.

If you’ve already used tirzepatide or semaglutide and are considering retatrutide, consult your prescriber about whether the glucagon receptor addition aligns with your metabolic goals. Compare the pre-filled pen option if reconstitution feels like a barrier to consistency.

For legal clarity, explore SAHPRA Section 21 named-patient access through a registered South African doctor if you want a fully regulated pathway. Verify current pricing and stock on Beskinny.store or competing local resellers before placing an order.

References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al.). New England Journal of Medicine / PubMed, 2023.
2. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, Jastreboff et al.). New England Journal of Medicine / PubMed, 2022.
3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, Wilding et al.). New England Journal of Medicine / PubMed, 2021.
4. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b multiple-ascending-dose trial (Urva et al.). The Lancet / PubMed, 2022.
5. MOUNJARO (tirzepatide) Prescribing Information. DailyMed, U.S. National Library of Medicine, 2025.
6. Guideline for Section 21 Access to Unregistered Medicines. SAHPRA, 2022.
7. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1, NCT05929066). ClinicalTrials.gov, U.S. National Library of Medicine, 2026.